Home Multiple Chinese Pharma License-out Deals Closed in Early October 2026 Amid Surge in Platform-Based Partnerships

Multiple Chinese Pharma License-out Deals Closed in Early October 2026 Amid Surge in Platform-Based Partnerships

Oct 09, 2026 14:17 CST Updated 14:17
Asieris

Innovative Drug Developer

Theramex

Developer of Women's Health Products

Abogen

Nucleic Acid Drug Developer

  【Pharmaceutical Network | Industry Trends] Data shows that between 2025 and 2030, the global pharmaceutical industry faces the risk of losing patent exclusivity for prescription drugs with revenues exceeding $300 billion. Against this backdrop, numerous multinational pharmaceutical companies have begun accelerating their acquisition of innovative assets from China. It is reported that in the first week of October 2026, several license-out deals were already completed by domestic pharmaceutical companies, involving Asieris Pharmaceuticals and Abogen Biosciences.
 
On October 7, Asieris Pharmaceuticals announced that it had signed an Exclusive License Agreement with Theramex HQ UK Limited, a specialty pharmaceutical company focused on women's health, granting the latter exclusive rights to APL-1702 (brand name: Cevira®) in European countries as well as Australia, New Zealand, and Turkey.
 
According to the announcement, Asieris will receive a $15 million upfront payment, an $11 million near-term regulatory milestone payment, as well as subsequent commercialization milestones and tiered sales royalties, with the total transaction value exceeding $250 million.
 
The essence of this transaction is to exchange regional rights for commercialization capabilities. Asieris has retained the rights for Greater China and other markets, while entrusting the registration and commercialization in regulated markets such as Europe to Theramex, which possesses mature local channels. This represents a pragmatic “borrowing a ship to go overseas” strategy.
 
On October 2, Abogen and Novartis reached a licensing and collaboration agreement with a total value of up to $7.8 billion. Under the terms of the agreement, Novartis will make an upfront payment of $575 million to secure exclusive rights to Abogen’s experimental drug ABO2203, along with options for other potential projects within Abogen’s RNA technology platform.
 
ABO2203 is an mRNA-encoded T-cell engager that enables patients to produce therapeutic molecules endogenously, targeting and eliminating B cells that drive autoimmune diseases, with the aim of fundamentally resetting the immune system. The drug’s potential indications cover a range of autoimmune disorders, including lupus and rheumatoid arthritis.
 
Through this collaboration, Novartis not only secured global rights to the mRNA-encoded CD19xCD3 TCE molecule but also obtained an exclusive option to develop additional programs based on Abogen’s RNA platform. Therefore, this is not a single-molecule license but a combined deal structured as “molecule plus platform options.”
 
Industry observers believe that these two cases demonstrate a shift in the focus of licensing deals from “validated clinical assets” to “early-stage differentiated molecules and technology platforms.” It is reported that more than half of the innovative Chinese drugs going global in 2025 were at the preclinical or Phase I stage at the time of licensing. For instance, Hengrui’s $15.2 billion collaboration with BMS covers 13 early-stage projects, while Innovent’s $10.5 billion partnership with Pfizer encompasses 12 early-stage oncology pipeline assets. Furthermore, the transition of deal targets from “single products” to “platform output capabilities” signifies that Chinese pharmaceutical companies are shifting their role at the negotiating table from “selling molecules” to “selling systems.”
 
Overall, China’s innovative drugs are accelerating their transition from being “asset suppliers” in the global industry chain to becoming “global development partners sharing risks.” Meanwhile, the positioning of Chinese innovative assets in the global value chain is shifting from an “optional choice” to a “must-have,” with transaction values expected to continue rising in the future.
 
  Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.